ข้ามไปยังเนื้อหาหลัก

ENGLISH · EVIDENCE OVERVIEW

Ligandrol / LGD-4033
evidence profile

Nonsteroidal selective androgen receptor modulator candidate. This page provides a concise English boundary and links back to the complete source-rich Thai profile.

Ligandrol / LGD-4033: conceptual scientific illustration for Clinical / Endocrine Pharmacology
VISUAL GUIDE · Ligandrol / LGD-4033

Clinical / Endocrine Pharmacology

Conceptual educational illustration. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

Ligandrol and LGD-4033 identify an investigational nonsteroidal SARM candidate. A 21-day placebo-controlled study in 76 healthy men found an exposure-related lean-mass signal alongside suppression of total testosterone, SHBG and HDL. The study was too small and short to establish clinical or bodybuilding benefit or long-term safety. FDA identifies marketed LGD-4033 products as unapproved drugs, and WADA 2026 prohibits ligandrol at all times.

01

ENTITY FACTS

What should readers identify first?

MOLECULELigandrol / LGD-4033
PHARMACOLOGYNonsteroidal selective androgen receptor modulator candidate
PRIMECORE CLASSB
EVIDENCE GRADEB
RESEARCH TOPICClinical / Endocrine Pharmacology
LAST REVIEWED2026-09-01
02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is Ligandrol / LGD-4033?

Ligandrol / LGD-4033 is described pharmacologically as Nonsteroidal selective androgen receptor modulator candidate. Ligandrol and LGD-4033 identify an investigational nonsteroidal SARM candidate. A 21-day placebo-controlled study in 76 healthy men found an exposure-related lean-mass signal alongside suppression of total testosterone, SHBG and HDL. The study was too small and short to establish clinical or bodybuilding benefit or long-term safety. FDA identifies marketed LGD-4033 products as unapproved drugs, and WADA 2026 prohibits ligandrol at all times.

Does Ligandrol / LGD-4033 have strong evidence?

PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is Ligandrol / LGD-4033 approved everywhere?

No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

LINE · สอบถามข้อมูลทั่วไปติดต่อฝ่ายข้อมูลทั่วไปLINE · GENERAL SUPPORTGeneral enquiries@primecoreสำหรับข้อมูลทั่วไปเท่านั้น · ไม่มีบริการด้านการขายหรือคำแนะนำทางการแพทย์General information only · No sales or medical advice